Overview

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Status:
Recruiting

Trial end date:
2025-10-22

Target enrollment:

Participant gender:

Summary

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Eisai Inc.

Treatments:

Lenvatinib
Pembrolizumab